Correlation Between Upstream Bio, and Eupraxia Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Upstream Bio, and Eupraxia Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Upstream Bio, and Eupraxia Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Upstream Bio, and Eupraxia Pharmaceuticals Common, you can compare the effects of market volatilities on Upstream Bio, and Eupraxia Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Upstream Bio, with a short position of Eupraxia Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Upstream Bio, and Eupraxia Pharmaceuticals.

Diversification Opportunities for Upstream Bio, and Eupraxia Pharmaceuticals

0.0

Correlation Coefficient

Upstream Bio,  Eupraxia Pharmaceuticals

Pay attention - limited upside

The 3 months correlation between Upstream and Eupraxia is 0.0. Overlapping area represents the amount of risk that can be diversified away by holding Upstream Bio, and Eupraxia Pharmaceuticals Commo in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Eupraxia Pharmaceuticals and Upstream Bio, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Upstream Bio, are associated (or correlated) with Eupraxia Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Eupraxia Pharmaceuticals has no effect on the direction of Upstream Bio, i.e., Upstream Bio, and Eupraxia Pharmaceuticals go up and down completely randomly.

Pair Corralation between Upstream Bio, and Eupraxia Pharmaceuticals

Considering the 90-day investment horizon Upstream Bio, is expected to under-perform the Eupraxia Pharmaceuticals. In addition to that, Upstream Bio, is 2.11 times more volatile than Eupraxia Pharmaceuticals Common. It trades about -0.14 of its total potential returns per unit of risk. Eupraxia Pharmaceuticals Common is currently generating about -0.02 per unit of volatility. If you would invest  325.00  in Eupraxia Pharmaceuticals Common on October 4, 2024 and sell it today you would lose (8.00) from holding Eupraxia Pharmaceuticals Common or give up 2.46% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Flat
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Upstream Bio,  vs.  Eupraxia Pharmaceuticals Commo

Upstream Bio,

Risk-Adjusted Performance

1 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Upstream Bio, are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Upstream Bio, may actually be approaching a critical reversion point that can send shares even higher in February 2025.

Eupraxia Pharmaceuticals

Risk-Adjusted Performance

6 of 100

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Eupraxia Pharmaceuticals Common are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Eupraxia Pharmaceuticals showed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Upstream Bio, and Eupraxia Pharmaceuticals

The main advantage of trading using opposite Upstream Bio, and Eupraxia Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Upstream Bio, position performs unexpectedly, Eupraxia Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eupraxia Pharmaceuticals will offset losses from the drop in Eupraxia Pharmaceuticals' long position.

The idea behind Upstream Bio, and Eupraxia Pharmaceuticals Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.